--- title: Who's missing out? The truth behind food allergy treatment approvals description: Explore national demographic trends and insurance approval rates for omalizumab use in treating IgE-mediated food allergies since FDA approval. image: https://blog.healthverity.com/hubfs/the-truth-behind-food-allergy-blog.png --- Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/) - [Contact](https://healthverity.com/contact/) - [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/) [![HealthVerity-Logo-Dark-3](https://blog.healthverity.com/hs-fs/hubfs/HealthVerity-Logo-Dark-3.png?width=1662&height=320&name=HealthVerity-Logo-Dark-3.png)](https://healthverity.com/) - How We Help - Featured Content - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Life Sciences](https://healthverity.com/life-sciences/) - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - Data Ecosystem - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/) - [Media Measurement](https://healthverity.com/media-measurement/) - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/) - Technology Products - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - [HealthVerity FLOW](https://healthverity.com/flow/portal/) - [Governance Manager](https://healthverity.com/governance-manager/) - [Smart Contracts](https://healthverity.com/smart-contracts-manager/) - Symphony - Symphony Health Platform - [Symphony Health Overview](https://healthverity.com/symphony-health/overview/) - [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - Symphony Solutions - [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/) - [HealthRankings](https://healthverity.com/symphony-health/health-rankings/) - [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/) - [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/) - [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/) - Symphony Products - [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf) - [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf) - [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf) - [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf) - [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf) - [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf) - [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf) - [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf) - Symphony Technology - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf) - [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/) - Who We Serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) - Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) - [Zombie Data Explained](https://healthverity.com/get-verified/) - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) [Contact](https://healthverity.com/contact/) [Sign In](https://marketplace.healthverity.com/) [![Logo](https://blog.healthverity.com/hubfs/social-suggested-images/healthverity.comwp-contentuploadshealthverity-2023-logo2x.png)](https://healthverity.com/) - How We Help - Symphony - Who We Serve - Resources - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) Featured Content ###### HealthVerity MarketplaceTM The nation’s largest healthcare and consumer data ecosystem ###### taXonomy Pathways Unique features per therapeutic area with claims, labs and EHR including notes ###### HealthVerity eXOs AI-native real-world evidence generation ###### Identity Manager (HVID) Standalone de-identification as a service Data Ecosystem HealthVerity MarketplaceTM HealthVerity TaxonomySM HealthVerity Notes Precision Event Alerts HealthVerity Mastersets Media Measurement Syndicated Audiences Insurance Underwriting Technology Products Identity Manager (HVID) HealthVerity for Clinical Trial Linkage HealthVerity for Commercial Smart Contracts HealthVerity for Registries Symphony Health Platform ###### Symphony Health Overview Seamless Data. Stronger Insights. Smarter Decisions. ###### Integrated Dataverse Integrated Dataverse (IDV®) is de-identified claims data platform that combines medical, hospital, prescription, and demographic data into a single unifed view. ###### Symphony HealthCloud Securely store, integrate, access, and analyze virtually unlimited volumes of data with Symphony HealthCloud. Symphony Solutions Health technology and business intelligence solutions Integrated Dataverse and Source Solutions Brand strategy and sales HealthRankings Market access Patient Journey Medicines affordability Symphony Products PayerSource® PrescriberSource® PatientSource® PatientSourceCompleteTM PatientSourceDUOTM Symphony FLEXTM CustomerSource® DiagnosticSource® NonRetailSource® Symphony Technology Symphony HealthCloud Synoma Data Integration Vantage Applications Metys ###### Life Sciences Technology solutions from development through commercialization ###### Channel Partners HealthVerity enables partners to unlock unprecedented value and insights for clients ###### Government Comprehensive and compliant solutions to manage the nation’s care ###### Data Ecosystem Partners Join the nation’s largest data partner ecosystem ###### Insurance Insurance-grade solutions that excel in managing risk and rebates ###### HealthVerity Blog Insights and updates from industry experts ###### Publications Peer-reviewed research and discoveries ###### News & Events Stay informed about our latest announcements and happenings ###### The IPGE Approach Fundamentals that power everything that we do and every solution we offer ###### Resource Library Explore guides, webinars, and tools to enhance your understanding ###### Zombie Data Explained Learn how data quality drives better research outcomes [Commercial Pharmaceutical](https://blog.healthverity.com/tag/commercial-pharmaceutical), [Case Studies](https://blog.healthverity.com/tag/case-studies), [Marketplace](https://blog.healthverity.com/tag/marketplace) # Who's missing out? The truth behind food allergy treatment approvals [By - HealthVerity,](https://blog.healthverity.com/author/healthverity) July 29, 2025 ![](https://blog.healthverity.com/hubfs/the-truth-behind-food-allergy-blog.png) ## Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs) pose a significant health risk due to their potential to cause life-threatening reactions, such as anaphylaxis. These conditions represent a critical area of public health surveillance, impacting millions of patients and placing considerable strain on healthcare systems. On February 16, 2024, the FDA approved a biologic therapy, omalizumab (brand name Xolair), for IgE-mediated food allergies, marking an important milestone in allergy treatment, but the data shows an interesting trend.1  Utilizing the nation's largest healthcare and consumer data ecosystem, [HealthVerity Marketplace](https://healthverity.com/marketplace/) enabled researchers to examine national healthcare medical claims and pharmacy claims data, providing unmatched coverage and source-stability to analyze treatment patterns.1 ## Precision in allergy treatment: understanding IgE mechanisms and omalizumab IgE-mediated food allergies occur when the immune system mistakenly identifies specific food proteins as harmful, triggering IgE antibodies that activate mast cells and basophils. This activation releases histamine and other mediators, causing allergic reactions ranging from mild to severe.2 The newly approved biologic, omalizumab, is a monoclonal antibody that selectively binds free IgE, reducing allergic sensitivity and the likelihood of severe reactions. Its approval signifies an essential therapeutic advancement, offering precision treatment to affected patients.2   ## Transparency and rigor in methodology: claims-based analysis This retrospective claims-based analysis used healthcare and pharmacy claims data from the [HealthVerity Marketplace](https://healthverity.com/marketplace/).1 Researchers identified medical claims for food allergy diagnoses (ICD-10 code Z91.01) and pharmacy claims for the biologic treatment omalizumab between January 1, 2012, and August 15, 2024. Transparency in data sourcing and explicit governance standards ensured clear, verifiable results. Figure 1 shows the overlap between patients diagnosed with food allergies and those who received omalizumab therapy, providing detailed demographic insights. ## Demographic insights and utilization trends of omalizumab The analysis identified a total of 18.9 million healthcare claims for food allergies and 67,000 pharmacy claims for omalizumab. However, only 14,000 of these claims overlapped, representing just 0.07% of food allergy claims. ![](https://lh7-rt.googleusercontent.com/docsz/AD_4nXfVcYhr0jB_RCD7okGCPed7BhBktl7Kv-8llU5LmblDMu2kBqBXi_N3fQZH9xfPrNpZKkEDi_3qElqHRmVJSjErBOucrfjMDteBj6HQKhhxYkqr4htqXop1jaPcSC5u0RC-1eer?key=GMX1wOEbwJqhJtgKof1GPw) Figure 1: The overlap between patients diagnosed with food allergies and those who received omalizumab therapy. Only 14,000 patients diagnosed with food allergies received omalizumab as a therapy (pink overlap). Data from Wan et al., 2025    Among those patients approved for omalizumab treatment, demographic patterns emerged (Figure 2): - 81.6% female, 18.4% male - Age distribution: - 0-17 years: 16.0% - 18-44 years: 35.8% - 45-64 years: 44.9% - 65 and older: 3.3% ![](https://lh7-rt.googleusercontent.com/docsz/AD_4nXeYShaJqL3axiOANDCRH1E-2dVvvL6RRqRGGfgf6T4NdU1KCvjm6DLuXmkRa_WihGNT5yBTv7TnkPINWLmeGhXgO3BrudodZ_cjApHVouyuRU3Lulu1nwhFi1G6YsoxyZ4kRbPZmA?key=GMX1wOEbwJqhJtgKof1GPw) Figure 2: Gender and age demographic patterns for patients approved for omalizumab treatment from Wan et al., 2025  ## Stability of market access and strategic insights The study's findings underscore the relatively low early adoption of omalizumab, highlighting stability concerns around market penetration and insurance approval processes. Pharmaceutical companies can use these insights to develop targeted strategies, improving market access, provider education, and patient advocacy. For government and public health authorities, this analysis using HealthVerity Marketplace provides a stable foundation for ongoing surveillance and identification of access disparities, guiding policy development and resource allocation to enhance patient outcomes. ## Using HealthVerity Marketplace for actionable insights **[HealthVerity Marketplace](https://healthverity.com/marketplace/) provides Verified access to:** - **Precise** demographic insights through linked, privacy-compliant claims data - **Transparent** treatment adoption patterns across diverse populations - **Stable** data sources that support reliable longitudinal analyses We cover more use-cases and explore how HealthVerity Marketplace works in our webinar, [watch a replay or read more here](https://blog.healthverity.com/the-marketplace-model-is-winning-key-insights-from-our-webinar).   [![Explore real-world data in HealthVerity Marketplace ](https://no-cache.hubspot.com/cta/default/5412465/interactive-192965525172.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLL4VVNe%2Fkf%2FQtI53zO3tYaqve52oSV6LYLTsOY205eCiJyOMbA%2BrJO78xy%2FwOADHxgZzbc5TDRLDFCEAxK5oAJsMf5fogubHRFtGvJo7UeLnq%2FVDpdkiLN%2FBArn5SG9zrH6R0tgMXdf0sdisqQCngW36Gj8yzhB4BfPpqdOidLmGoCbU8nVbaaL3uehS%2Flm%2BirOcDtKaAjxyoV%2FRmqfoo5d&webInteractiveContentId=192965525172&portalId=5412465) # References 1. Wan L, Lee-wong M, Promisloff R, et al. National demographic trends and approval rates for omalizumab use to treat food allergy: a retrospective claims-based analysis since fda approval. Journal of Allergy and Clinical Immunology. 2025;155(2):AB139. 2. Bégin, P., Waserman, S., Protudjer, J.L.P. *et al.* Immunoglobulin E (IgE)-mediated food allergy. *Allergy Asthma Clin Immunol* 20 (Suppl 3), 75 (2024).     ###### Category - [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices) - [Trends & Insights](https://blog.healthverity.com/tag/trends-insights) - [HEOR](https://blog.healthverity.com/tag/heor) - [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership) - [Marketplace](https://blog.healthverity.com/tag/marketplace) - [taXonomy](https://blog.healthverity.com/tag/taxonomy) - [Industry Updates](https://blog.healthverity.com/tag/industry-updates) - [Case Studies](https://blog.healthverity.com/tag/case-studies) - [Commercial Pharmaceutical](https://blog.healthverity.com/tag/commercial-pharmaceutical) - [Government](https://blog.healthverity.com/tag/government) - [AI](https://blog.healthverity.com/tag/ai) - [eXOs](https://blog.healthverity.com/tag/exos) - [Audiences](https://blog.healthverity.com/tag/audiences) - [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways) - [Notes](https://blog.healthverity.com/tag/notes) - [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases) ###### Popular Post - [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) - [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) - [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims) - [What is Privacy Preserving Record Linkage (PPRL)?](https://blog.healthverity.com/what-is-privacy-preserving-record-linkage) - [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) ###### Subscribe ### Similar Blogs [![Accelerating the path to regulatory submission with RWD](https://blog.healthverity.com/hs-fs/hubfs/Accelerating%20the%20path%20to%20regulatory%20submission%20with%20RWD.png?width=352&name=Accelerating%20the%20path%20to%20regulatory%20submission%20with%20RWD.png)](https://blog.healthverity.com/accelerating-the-path-to-regulatory-submission-with-rwd) #### [Accelerating the path to regulatory submission with RWD](https://blog.healthverity.com/accelerating-the-path-to-regulatory-submission-with-rwd) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 27 March 2024 The use of real-world data (RWD) in pharmaceutical development is becoming increasingly prevalent... [READ MORE](https://blog.healthverity.com/whos-missing-out-the-truth-behind-food-allergy-treatment-approvals) [![How FDA’s New Real-World Data Guidance Solves 3 Big Problems](https://blog.healthverity.com/hs-fs/hubfs/Three%20pain%20points%20the%20latest%20FDA%20real-world%20data%20guidelines%20can%20address.png?width=352&name=Three%20pain%20points%20the%20latest%20FDA%20real-world%20data%20guidelines%20can%20address.png)](https://blog.healthverity.com/three-pain-points-the-latest-fda-real-world-data-guidelines-can-address) #### [How FDA’s New Real-World Data Guidance Solves 3 Big Problems](https://blog.healthverity.com/three-pain-points-the-latest-fda-real-world-data-guidelines-can-address) By [TJ Van Bemmel, senior director, technical solutions](https://blog.healthverity.com/author/tj-van-bemmel-senior-director-technical-solutions) 17 October 2023 In case you missed it, at the end of August, the FDA released new guidance on how to approach... [READ MORE](https://blog.healthverity.com/whos-missing-out-the-truth-behind-food-allergy-treatment-approvals) [![How the FDA is using real-world evidence in safety and approval decisions](https://blog.healthverity.com/hs-fs/hubfs/fda-rwe-approval-blog.png?width=352&name=fda-rwe-approval-blog.png)](https://blog.healthverity.com/how-the-fda-is-using-real-world-evidence-in-safety-and-approval-decisions) #### [How the FDA is using real-world evidence in safety and approval decisions](https://blog.healthverity.com/how-the-fda-is-using-real-world-evidence-in-safety-and-approval-decisions) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 18 December 2025 Regulatory decision-making depends on evidence that reflects how medical products perform in... [READ MORE](https://blog.healthverity.com/whos-missing-out-the-truth-behind-food-allergy-treatment-approvals) #### Who we serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) #### How we help - [HealthVerity Marketplace](https://healthverity.com/marketplace/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/) - [HealthVerity FLOW](https://healthverity.com/flow/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) #### Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) #### Our company - [About Us](https://healthverity.com/about-us/) - [Leadership](https://healthverity.com/about-us/#leadership) - [Board of Directors](https://healthverity.com/about-us/#board) - [Careers](https://healthverity.com/careers/) - [Contact](https://healthverity.com/contact/) ©2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/) ![](https://px.ads.linkedin.com/collect/?pid=4361946&fmt=gif) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "articleSection" : "HealthVerity Marketplace", "author" : { "@type" : "Organization", "name" : "HealthVerity" }, "dateModified" : "2025-08-12", "datePublished" : "2025-07-29", "description" : "Real-world data shows who’s getting access to newly approved food allergy treatments like omalizumab, where gaps persist, and how linked data can guide equitable uptake and outcomes.", "headline" : "Who's missing out? The truth behind food allergy treatment approvals", "keywords" : [ "food allergy", "omalizumab", "Xolair", "treatment approvals", "access disparities", "Real world data", "RWE", "HealthVerity Marketplace" ], "mainEntityOfPage" : { "@id" : "https://blog.healthverity.com/whos-missing-out-the-truth-behind-food-allergy-treatment-approvals", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.healthverity.com/hubfs/healthverity-logo.png" }, "name" : "HealthVerity" }, "url" : "https://blog.healthverity.com/whos-missing-out-the-truth-behind-food-allergy-treatment-approvals" } ``` ```json { "@context" : "https://schema.org", "@type" : "FAQPage", "mainEntity" : [ { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "It examines real-world access to newly approved food allergy treatments, highlighting which patient groups are benefiting, where gaps remain, and how linked data can inform equitable adoption." }, "name" : "What is the post about?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "The post discusses omalizumab (Xolair) and how real-world data can track its uptake and outcomes following FDA approval." }, "name" : "Which treatment does the analysis focus on?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "De-identified, linked real-world data from HealthVerity Marketplace, enabling longitudinal views across claims and clinical sources while maintaining HIPAA compliance." }, "name" : "What data sources are used?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Manufacturers, payers, and providers can use the findings to identify underserved populations, refine outreach, and measure outcomes." }, "name" : "Who can use these insights?" } ] } ``` ```json { "@context" : "https://schema.org", "@type" : "BreadcrumbList", "itemListElement" : [ { "@type" : "ListItem", "item" : "https://www.healthverity.com/", "name" : "Home", "position" : 1 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/", "name" : "Blog", "position" : 2 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/whos-missing-out-the-truth-behind-food-allergy-treatment-approvals", "name" : "Who's missing out? The truth behind food allergy treatment approvals", "position" : 3 } ] } ```